AiMOGA Robotics, a Chery brand, will debut Mobo, its first consumer-grade humanoid robot designed as a home companion, at the 2026 Chery International User Summit in Wuhu, China. Mobo features advanced AI for understanding complex commands, spatial awareness, and emotional gestures, aiming to assist families while respecting privacy. The launch marks AiMOGA's expansion from commercial to consumer markets, leveraging Chery's automotive tech expertise. Global pre-orders will open during the event from October 19-23, showcasing Mobo alongside other robotic products for public service and commercial use.
AiMOGA's new humanoid robot Mobo is the story's subject, with this market data for context. For readers following Technology-sector US stocks on Pluang, 11 of 150 stocks rose while 139 fell. Notable movers include FSLY at USD 22.47 with a -10.37% change and 87% buy orders, OKTA at USD 187.26 with a -10.20% change and 91% sell orders, and SMCI at USD 31.63 with a -9.86% change and 73% buy orders. Data is as of Oct 17, 2026 23:11 WIB.
Chery Auto will showcase its purpose-built Level 4 (L4) Robotaxi at the 2026 Chery International User Summit and sign a strategic cooperation agreement with UAE-based K2. The Robotaxi offers a fully driverless passenger experience from booking to rid...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer-grade humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Powered by AiMOGA's proprietary AI system MoAgent, Mobo can interpret complex command...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Mobo uses advanced AI to understand complex commands, navigate home environments, and remem...
AiMOGA Robotics, a brand under Chery, introduced Mobo, its first consumer-grade humanoid robot designed as a family companion, at the 2026 Chery International User Summit. Mobo operates with AiMOGA's proprietary MoAgent AI, enabling it to understand ...
Ascendis Pharma announced that the European Medicines Agency's CHMP has issued a positive opinion recommending approval of TransCon CNP (navepegritide), a once-weekly treatment for achondroplasia in children aged two and older with open growth plates...
